TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06746532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intranasal breast milk
Description: Own-mother's fresh breast milk (within 4 hours of having been expressed), is administered intranasally to neonates with hypoxic-ischemic encephalopathy receiving therapeutic hypothermia, starting from the first day of life and continuing for 28 days.~Dose: 2 times daily, 0.4 ml in each nostril.
Study: NCT05142345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTINUUM Intervention
Description: The intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consists of a video visit conducted by an oncology nurse practitioner within three business days of hospital discharge, to: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.
Study: NCT06571981

Intervention type: DEVICE
Intervention: TUP ultraportable US with teleradiology capacities
Description: Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
Study: NCT04765215

Intervention type: BIOLOGICAL
Intervention: CoronoVAC
Description: SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination

Intervention type: BIOLOGICAL
Intervention: CoronoVAC
Description: SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
Study: NCT05386576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42.
Study: NCT04743076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Endovascular treatment
Study: NCT06341374

Intervention type: BIOLOGICAL
Intervention: Influvac Tetra
Description: All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.
Study: NCT04743076

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical treatment
Study: NCT06025305

Intervention type: DIAGNOSTIC_TEST
Intervention: Intravascular imaging test
Description: Coronary artery disease patients first underwent CCTA and then intravascular imaging test within 3 months
Study: NCT06341374

Intervention type: BIOLOGICAL
Intervention: Influvac Tetra
Description: All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.

Intervention type: BIOLOGICAL
Intervention: Influvac Tetra
Description: All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.

Intervention type: BIOLOGICAL
Intervention: Influvac Tetra
Description: All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.
Study: NCT06571981

Intervention type: DEVICE
Intervention: CUS conventional ultrasound
Description: Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
Study: NCT06013852

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: processing the radiography with the Boneview software
Description: all X-Rays will be analysed with and without the software
Study: NCT06357715

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: slumpposition
Description: neurodynamic sliding mobilisation in the slump position
Study: NCT04893135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pratice physical activity
Description: treadmill walking : walk at a speed of 2.7 km.h-1 in 3 stages of 3 mins with an incline of 0%, 5% and 10%
Study: NCT06049108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3871801
Description: Administered orally
Study: NCT06244108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy home program
Description: After evaluating the children, an occupational therapy home intervention program will be developed for each child. The program will be monitored through telephone and computer interviews, as well as video, photo, and audio recordings. The interventions in this study were selected based on successful occupational therapy home programs for children with disabilities. The program consists of five steps.~Step 1 is to establish collaborative relationships with parents. Step 2 is to determine the most appropriate goals for the child and their family. Step 3 involves selecting the most suitable therapeutic activities to achieve these goals. Step 4 is to educate and support parents in performing these therapeutic activities. Finally, Step 5 involves measuring the results and providing feedback.
Study: NCT04945694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral pecto-intercostal fascial block
Description: - PATIENT IN SUPINE POSITION, SKIN WILL BE DISINFECTED, A HIGH-FREQUENCY LINEAR PROBE WILL BE PLACED PARALLEL TO LONGITUDINAL AXIS OF STERNUM ON LATERAL BORDER AND SCANNED LATERALLY TO IDENTIFY 4TH AND 5TH COSTAL CARTILAGE. THE PECTORALIS MAJOR MUSCLE (PMM), INTERNAL INTERCOSTAL MUSCLE (IIM), TRANSVERSUS THORACIS MUSCLE (TTM), RIBS, AND PLEURA WILL BE IDENTIFIED. COLOR DOPPLER ULTRASONOGRAPHY WILL BE USED TO DETERMINE PERFORATING BRANCHES OF INTERNAL THORACIC ARTERY, WHICH TRAVEL ANTERIORLY THROUGH THE ANTERIOR CHEST WALL, PIERCING THE INTERCOSTAL MUSCLE AND PMM. A 22G NEEDLE WILL BE INSERTED IN PLANE WITH PROBE, IN CAUDAL-TO-CRANIAL DIRECTION UNTIL THE TIP IS POSITIONED IN INTER- FASCIAL PLANE BETWEEN THE PMM AND IIM. NORMAL SALINE WILL BE USED TO DETERMINE CORRECT PLACEMENT OF NEEDLE TIP IN INTER-FASCIAL PLANE, AS SHOWN BY SEPARATION OF FASCIAL LAYERS THEN LOCAL ANESTHETIC WILL BE INJECTED

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous fentanyl
Description: In this group, patients will receive only incremental doses of intravenous fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atracurium
Description: Intravenous atracurium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atracurium
Description: Intravenous atracurium

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound-guided block
Study: NCT06556212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time feedback using smart swim goggles
Description: Smart swim goggles (Form Athletica Inc.) with activity metrics (such as heart rate, swimming pace, and workout instructions) displayed in real-time during a swimming activity.
Study: NCT04791956

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Daily intake of Inulin-type fructans from chicory
Study: NCT05142345

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients assigned to the usual care group will have their post-discharge follow-up scheduled per hospital, outpatient oncology team, and patient preference.
Study: NCT04940936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Patient Decision Aid
Description: The Patient Decision Aid informs about the pros and cons of each option
Study: NCT04633824

Intervention type: OTHER
Intervention: Retrospective Electronic Medical Record Review
Description: Patients will be assessed retrospectively for evidence of successful or failed epidural extension in the setting of need for cesarean section
Study: NCT04791956

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of maltodextrin
Study: NCT05401968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoporosis patient education
Description: During osteoporosis patient education the participants get knowledge about e.g. osteoporosis, medication, and diet, and they participate in physical exercises. Though, differences between municipalities exist. The participants meet in groups and face-to-face.
Study: NCT06357715

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: slumpposition
Description: neurodynamic sliding mobilisation in the slump position

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no slump position
Description: placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no slump position
Description: placebo
Study: NCT05852340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritlecitinib
Description: ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritlecitinib
Description: ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritlecitinib
Description: ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritlecitinib
Description: ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritlecitinib
Description: ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)
Study: NCT05278104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zentiva®
Description: Zentiva®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06284408

Intervention type: OTHER
Group type: OTHER
Intervention: Centralized Screening Unit Implementation
Description: The CSU provides a proactive and comprehensive population health approach to screening. This includes core functions of a) patient identification, b) contact, c) engagement, education and support, d) referral and navigation to LDCT screening, e) post screening follow-up, and f) retention
Study: NCT06276465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darolutamide 300 mg
Description: 2 tablets of 300 mg twice daily (=1200 mg/day) up to 5 years from randomisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide 300 mg
Description: 2 tablets of 300 mg twice daily (=1200 mg/day) up to 5 years from randomisation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Over one week,30 Gy in 3 fractions of 10 Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy
Description: Continuous ADT during the study course. The choice of ADT is left to the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Continuous ADT during the study course. The choice of ADT is left to the discretion of the investigator.
Study: NCT05800574

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy (5 days for 7 weeks)
Description: Mon-Fri (5 days for 7 weeks), total 35 fractions over 35 treatment days of radiation therapy (RT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy (5 days for 6 weeks)
Description: Mon-Fri (5 days for 6 weeks), total 35 fractions over 30 treatment days of RT (two doses 6 hours apart except for the last 6th Friday of the 6 weeks )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 40mg/m2 (weekly for 7 weeks)
Study: NCT05667142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: XEN1101 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: XEN1101 capsules
Study: NCT05139069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Toolkit
Description: Staff in this intervention will be trained to conducting intimate partner violence screening, and providing support to women through referrals to local community resources; to help African American women identify and understand HIV risk factors (e.g., unprotected condom less sex with a male partner who is HIV-positive or unknown HIV status); and to communicate with their African American women patients in a respectful way in order to build trust and facilitate shared decision making.
Study: NCT06219005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ultrasound education and simulation workshop
Description: workshop testing emergency physician knowledge and technical skills in performing ultrasound-guided nerve blocks in a simulation model
Study: NCT05236673

Intervention type: DRUG
Intervention: JARDIANCE®
Description: JARDIANCE® film-coated tablets 10mg
Study: NCT05925803

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab (blinded)
Description: Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (blinded)
Description: matched placebo delivered subcutaneously, once weekly for 52 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab (unblinded, open label)
Description: At Week 52, all patients will receive Anifrolumab subcutaneously once weekly for 52 weeks
Study: NCT05110157

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: Oral capsules
Study: NCT06358417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition-enhanced CHW
Description: CHW provides nutrition education and skills training in addition to the usual care (Basic CHW) hypertension management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic CHW
Description: CHW provide usual care for hypertension management.
Study: NCT04702893

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study: NCT05603104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: See arm description
Study: NCT06074861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fasting-mimicking diet + non-surgical periodontal therapy
Description: Test group will receive a full-mouth non-surgical periodontal therapy (also named professional mechanical plaque removal-PMPR) and, in the same day (starting at morning), a fasting-mimicking diet (FMD) will be started (for a cycle of 5 days). Other two cycles of FMD will be followed at 45- and 85- days after treatment, respectively.
Study: NCT05193383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Description: Session 1 (Day 1): Participants receive repeated exposure to mental imagery of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.
Study: NCT05616221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AP-PA02
Description: Bacteriophage administered via inhalation
Study: NCT05193383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach-avoidance conflict
Description: Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach-avoidance conflict
Description: Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo exposure
Description: Session 1 (Day 1): in vivo exposure. Participants receive repeated exposure to film clips of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
Study: NCT04623593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF
Description: Standard operative treatment for anterior cervical discectomy. Through a right or left-sided approach the disc space contents are resected. The endplates are prepared with curettes and the disc space contents are removed. The posterior longitudinal ligament is opened. The dura is visualized to ensure adequate decompression. A cage is implanted in the disc space. The disc removal and cage implantation can be performed at a single level or at multiple levels. The wound is closed in layers, after a prevertebral wound drain is placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACDA
Description: The start of the procedure is the same as in the ACDF group. After the discectomy, a cervical disc prosthesis is placed in the disc space instead of a cage, in accordance with the manufacturer's protocol for implantation and endplate preparation. The disc removal and arthrodesis implantation can be performed at a single level or at multiple levels. Wound closure is similar to the ACDF procedure.
Study: NCT06539195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: Daily dose of DZD8586 at 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: Daily dose of DZD8586 at 50 mg
Study: NCT03532958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNZ-1
Description: PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
Study: NCT06539195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: Daily dose of DZD8586 at 75 mg
Study: NCT05064423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Trials Education Program
Description: The Community Health Educator (CHE) will provide CT education and outreach to increase clinical trial knowledge and the importance of clinical trials research and participation. The clinical trials educational activities will include the use of NCI Colorectal Cancer resources and materials, including a PowerPoint presentation, clinical trials information, and online resources. The CHE will tailor the PowerPoint slides to ensure that they are culturally tailored, visually appealing, low-literacy, language appropriate and include appropriate visuals. The CTs educational sessions will be delivered in Spanish and English and will take approximately 45 minutes to 1 hour.
Study: NCT04347967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UMC119-06
Description: Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
Study: NCT05509660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUMA+
Description: Transdiagnostic CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PUMA
Description: Transdiagnostic CBT
Study: NCT03532958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Dose volume consistent with weight-based dosing of BNZ-1
Study: NCT06124924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: a starting dose of a SGLT2i will be prescribed for the participant for pickup at discharge via the UMMC discharge pharmacy. The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills, but this can be adjusted to other SGLT2i or other doses in the outpatient setting by either Dr. Murphy or by the participants' established providers, typically based on insurance company preferences among the three FDA-approved SGLT2i.
Study: NCT05407636

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ABBV-RGX-314 Dose 1
Description: AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ABBV-RGX-314 Dose 2
Description: AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept (EYLEA®)
Description: 2.0 mg (0.05 mL solution) administered by intravitreal injection approximately every 8 weeks after 3 monthly injections~Other Names:~• Eylea (anti-VEGF agent)
Study: NCT05245175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium chloride particles
Description: Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactose particles
Description: Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clean air
Description: Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium chloride particles with house dust mite
Description: Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactose particles with house dust mite
Description: Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.